Biotechnology News and Research

RSS

Osteotech reports overall sequential revenue growth of 117% for first-quarter 2010

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the first quarter ended March 31, 2010.

10 May 2010

Lexicon Pharmaceuticals first-quarter revenues down 61%

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2010.

10 May 2010

American Oriental Bioengineering first-quarter revenue increases 16.7% to $53.7 million

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the first quarter ended March 31, 2010.

10 May 2010

Evotec and Genentech sign drug discovery deal

Evotec AG today announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group (SWX:RO) (SIX:ROG) (Pink Sheets:RHHBY), to discover novel small molecule therapeutics.

10 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

S2S hosts students from Newark Science Park High School for a day of hands-on science

Students 2 Science, Inc. hosted students from Newark Science Park High School for a day of hands-on science as part of its year-long "Supercharged Science" program.

7 May 2010

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

7 May 2010

Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.

7 May 2010

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the first quarter ended March 31, 2010. The Company also highlighted key commercial and regulatory progress during the quarter, and provided its expected milestones for the remainder of 2010.

7 May 2010

Warner Chilcott reports 209.5% increase in first-quarter 2010 revenues

Warner Chilcott plc today announced its results for the quarter ended March 31, 2010. Revenue in the quarter was $761.3 million, an increase of $515.3 million, or 209.5%, over the prior year quarter.

7 May 2010

Gene patenting policies affect patient access to testing for disease-causing genes: Study

Policies allowing genes to be patented can make it more difficult for patients to access testing for important disease-causing gene mutations, according to a series of papers in a special online supplement published by Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.

7 May 2010

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $210,300 to Amicus Therapeutics (Cranbury, NJ) to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer's disease.

7 May 2010

Neurons' complicated tree-like structure formation unravelled

A breakthrough about the formation and maintenance of tree-like nerve cell structures could have future applications in the treatment of neurodegenerative diseases and the repair of injuries in which neurons are damaged. The findings by the international team led by Prof. Benjamin Podbilewicz of the Technion-Israel Institute of Technology Faculty of Biology are published in the May 6th issue of Science Express.

7 May 2010

New CD4 test kit can improve quality of life for HIV and AIDS patients

The use of rapid point-of-care diagnostic tests for the measurement of CD4 T-cells, a marker of the immune system will be an important factor in improving the lives of people living with HIV and AIDS especially in developing and resource-poor countries.

7 May 2010

New study may help design better vaccines for dengue fever

Some of the human immune system's defences against the virus that causes dengue fever actually help the virus to infect more cells, according to new research published today in the journal Science.

7 May 2010

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that researchers from Pfizer, Inc. presented data on in vivo activity of PF-04523655 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 2-6, 2010 in Fort Lauderdale.

7 May 2010

Genzyme to initiate $2 billion stock buyback

Genzyme Corp. today announced that its Board of Directors has voted to pursue several actions to increase shareholder value. The company will initiate a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt. The additional $1 billion of stock will be repurchased during the next 12 months.

7 May 2010

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, reported today results for the recently completed Phase 2b non-FDA clinical trial of its flagship oral insulin capsule, ORMD-0801.

7 May 2010

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.

6 May 2010

Biotechnology News and Research

Osteotech reports overall sequential revenue growth of 117% for first-quarter 2010

Lexicon Pharmaceuticals first-quarter revenues down 61%

American Oriental Bioengineering first-quarter revenue increases 16.7% to $53.7 million

Evotec and Genentech sign drug discovery deal

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

S2S hosts students from Newark Science Park High School for a day of hands-on science

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

Warner Chilcott reports 209.5% increase in first-quarter 2010 revenues

Gene patenting policies affect patient access to testing for disease-causing genes: Study

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

Neurons' complicated tree-like structure formation unravelled

New CD4 test kit can improve quality of life for HIV and AIDS patients

New study may help design better vaccines for dengue fever

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

Genzyme to initiate $2 billion stock buyback

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News